Comparison of the effects of opicapone and Madopar
Medoba is the brand name of Dopaserazine tablets marketed in China. Opicapone (opicapone) and Medoba (Medoba) are both drugs used to treat Parkinson's disease, but they have some differences. The specific use should be judged and decided by the doctor based on the patient's condition. Opicapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor. It inhibits the activity of COMT enzyme and prolongs the action time of dopamine in the brain, thereby enhancing the effect of dopamine. Madopar is a dopamine agonist that directly stimulates dopamine receptors, increasing dopamine concentrations in the brain.
Opicapone is commonly used in dopamine replacement therapy in patients with Parkinson's disease to control the progression of the disease and reduce symptoms of dyskinesia. It is given as an oral tablet once a day. Common side effects include digestive problems such as nausea, vomiting, diarrhea and constipation. A small number of patients may experience other complaints such as headache, fatigue, and insomnia, but patients with liver disease should avoid opicapone. Madopar is also commonly used in the treatment of Parkinson's disease, especially in early-stage patients or in combination with other drugs to increase dopamine levels. It is given in the form of oral tablets or oral solutions. The specific medication method is determined according to the needs of the patient. Common side effects include nausea, vomiting, headache, insomnia and fatigue, but long-term use may lead to the downregulation of dopamine receptors, thereby weakening the effect of the drug.
Opicapone has not yet been launched in the country, so it is not covered by medical insurance. The European version of Opicapone’s original drug specifications listed overseasThe price per box of 50mg*90 capsules is around RMB 6,000 (the price may fluctuate due to the exchange rate). There is currently no generic version of Opicapone on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)